Tuesday, April 27, 2021 Daily Archives

Regeneron rejigs plans to build preclinical facility in NY state

by

Regeneron is reportedly injecting $480 million in a planned expansion at its campus in Greenburgh, New York including a preclinical manufacturing facility. According to various publications such as Westfair Online and Real Estate In-depth, Regeneron has designed a $480 million preclinical manufacturing facility at its Tarrytown campus in New York and proposed it to Westchester County’s Industrial Development Agency (IDA). The reported plan to build a 207,000 square-foot laboratory is said to have been amended from an initial proposal that…

April 27, 2021

ADC Therapeutics joins conjugate elite with Zynlonta FDA approval

by

The US FDA has approved Zynlonta (loncastuximab tesirine), the eleventh antibody-drug conjugate and the first for ADC Therapeutics. Zynlonta received the thumbs up from the US Food and Drug Administration (FDA) last week for the treatment of patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The antibody-drug conjugate (ADC) is composed of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine (PBD)-based cytotoxic warhead. PBDs are a class of compounds…

April 27, 2021

Biosimilars: Roche and Biogen talk competition, price, opportunities

by

The complexity of the biosimilar market was much in evidence last week with Roche and Biogen both citing competition as challenges in Q1. Roche saw group revenues of CHF 14.9 billion ($16.3 billion) in the first three months of 2021, up 3% year-on-year. The contribution from diagnostics grew 55% to CHF 4.5 billion due to a surge in demand for COVID-19 testing. In contrast, revenue from medicines fell 9% to CHF 10.6 billion. Roche said the decline was mainly because…

April 27, 2021